Osteonecrosis of the jaws: What the physician needs to know: Practical considerations

Disease-a-Month

Volumn 57, Issue 4, 2011, Pages 231-241

  Abughazaleh, Khaled ^a   Kawar, Nadia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BACTERIAL INFECTION; BONE METASTASIS; BONE NECROSIS; BONE TURNOVER; CLINICAL FEATURE; CLINICAL PRACTICE; CORTICOSTEROID INDUCED OSTEOPOROSIS; GENERAL PRACTITIONER; GINGIVITIS; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MORBIDITY; MYCOSIS; NEOPLASM; OSTEOMYELITIS; OSTEOPOROSIS; PAGET BONE DISEASE; PERIODONTAL DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PROFESSIONAL PRACTICE; RADIATION INJURY; RISK FACTOR; SINUSITIS;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HEAD AND NECK NEOPLASMS; HUMANS; JAW DISEASES; OSTEONECROSIS; RADIATION INJURIES;

EID: 79955766463     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.disamonth.2011.03.011     Document Type: Article

References (16)

1. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22(10):1479-1491.
2. Marx R.E. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983, 41:283.
3. Reuther T., Schuster T., Mende U., Kübler A. Osteoradionecrosis of the jaws as a side effect of radiotherapy of head and neck tumour patients-a report of a thirty-year retrospective review. Int J Oral Maxillofac Surg 2003, 32:289.
4. Marx R.E., Stern D. Oral and Maxillofacial Pathology. A Rational for Diagnosis and Treatment 2003, 383-394. Quintessence Publishing, Chicago, IL.
5. Rodan G.A., Fleisch H.A. Bisphosphonates: Mechanisms of action. J Clin Invest 1996, 97:2692.
6. Berenson J.R., Hillner B.E., Kyle R.A., et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002, 20:3719.
7. Regarding Fosamax (alendronate sodium) and rare cases of osteonecrosis of the jaw Merck & Co. Inc., Accessed January 4, 2011. http://www.merck.com/newsroom/press_releases/product/fosamax_statement.html.
8. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003, 61:1115.
9. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004, 62:527.
10. Ruggiero S.L., Dodson T.B., Leon A., et al. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteonecrosis of the Jaws-2009 Update. J Oral Maxillofac Surg 2009, 67(suppl 5):2-12.
11. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005, 23:8580.
12. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 2006, 24:945.
13. Jadu F., Lee L., Pharoah M., et al. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007, 18:2015.
14. Ripamonti C.I., Maniezzo M., Campa T., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009, 20:137.
15. Freiberger J.J. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2009, 67(suppl 1):96-106.
16. Aghaloo T.L., Felsenfeld A.L., Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010, 68:959-963.